Merck & Co., Inc. (mrk)
MRK — Company Overview
Merck & Co., Inc. (MRK) is a mega-cap company in the Healthcare sector, operating in Drug Manufacturers - General.
| Ticker | MRK |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $365.34B |
| Last price | $148.08 |
| Size category | Mega Cap |
MRK — Business Description
Merck & Co., Inc. (MRK) operates in Drug Manufacturers - General within the broader Healthcare market. Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax,…
Official website: https://www.merck.com.
MRK — Investment Thesis
The investment thesis for Merck & Co., Inc. (MRK) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 5.1% year-over-year (public data).
- Trailing P/E of 120.39× implies elevated growth expectations at the current price.
- Forward P/E (15.53×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.2% adds an income component to total return.
- Equity market capitalization is approximately $365.34B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
MRK — Financial Health
Financial health for Merck & Co., Inc. (MRK) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Profit margin near 4.8% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $15.17B supports balance-sheet flexibility. Debt-to-equity of 128.41 warrants monitoring in a higher-rate environment.
| Trailing P/E | 120.39× |
| Forward P/E | 15.53× |
| Price / Sales | 5.49× |
| Price / Book | 8.72× |
| Gross margin | 75.9% |
| Operating margin | -0.2% |
| Profit margin | 4.8% |
| Return on equity | 7.0% |
| Debt / Equity | 128.41 |
| Free cash flow | $15.17B |
MRK — Growth Outlook
Growth outlook for Merck & Co., Inc. (MRK) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 5.1% suggests steady but measured expansion.
- Price is 5.6% below the 52-week high.
MRK — Competitive Position
Merck & Co., Inc. (MRK) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $365.34B places MRK among mega-cap peers.
- Gross margin near 75.9% may reflect pricing power or favorable mix.
MRK — Strengths
Strengths for Merck & Co., Inc. (MRK) inferred from public financial metrics:
- Revenue growth of 5.1% year-over-year.
- Gross margin of 75.9% supports competitive unit economics.
- Positive free cash flow ($15.17B).
- Dividend yield of 2.2% for income-oriented holders.
- Mega Cap scale ($365.34B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
MRK — Weaknesses
Weaknesses and pressure points for Merck & Co., Inc. (MRK) based on available data:
- Elevated trailing P/E (120.39×) limits valuation margin of safety.
- Thin profit margin (4.8%).
MRK — Opportunities
- Dividend yield of 2.2% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
MRK — Risks
- Rich valuation (P/E 120.39×) increases downside if growth slows.
- Thin margins leave less room for operational missteps.
MRK — Summary
Merck & Co., Inc. (MRK) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $148.08 with market cap $365.34B. Trailing P/E 120.39×. Revenue grew 5.1% year-over-year per public data. Notable strengths include revenue growth of 5.1% year-over-year. Key watch items include elevated trailing p/e (120.39×) limits valuation margin of safety. Public estimates and earnings snapshots for Merck & Co., Inc. are on this site; ownership, live news, and deeper models remain in Vest Terminal.
Start Free — open MRK in Vest Terminal
Access live data, filings, ownership, and analysis for Merck & Co., Inc..
Merck & Co., Inc. FAQ
What does Merck & Co., Inc. (MRK) do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerb…
What is MRK's P/E ratio?
Merck & Co., Inc. has a trailing P/E of 120.39× based on publicly available market data.
Does MRK pay a dividend?
Indicated dividend yield: 2.2%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRK in?
Merck & Co., Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is MRK's market capitalization?
Approximate market cap: $365.34B.
What are the main risks for MRK?
Key risks include elevated valuation, among factors on this page.
What are the strengths of MRK?
Potential positives include revenue growth of 5.1% year-over-year, gross margin of 75.9% supports competitive unit economics.
Where can I get analyst estimates for MRK?
Public analyst price targets and consensus for Merck & Co., Inc. are on the free /stocks/mrk/estimates page. Deeper estimate history and models are available in Vest Terminal.